In:
Pharmacogenomics, Future Medicine Ltd, Vol. 21, No. 5 ( 2020-04), p. 325-335
Kurzfassung:
Aim: Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). Materials & methods: We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE – responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Results: Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p 〈 10 -5 ) but no significant association reflecting its limited power. The suggestive associations highlight candidate genes that are implicated in epileptogenesis and neurodevelopment. Conclusion: This first GWAS of AED response in GGE provides a comprehensive reference of SNP associations for hypothesis-driven candidate gene analyses in upcoming pharmacogenetic studies.
Materialart:
Online-Ressource
ISSN:
1462-2416
,
1744-8042
DOI:
10.2217/pgs-2019-0179
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2020
SSG:
15,3
Permalink